Article Text

Download PDFPDF
Human immunodeficiency virus testing in patients with invasive cervical carcinoma: a prospective trial of the gynecologic oncology group
  1. A. Calkins*,
  2. F. B. Stehman,
  3. B. Bundy,
  4. J. A. Benda§,
  5. R. S. Mannel,
  6. P. Seago,
  7. F. Cappuccini#,
  8. R. D. Alvarez**,
  9. B. J. Monk†† and
  10. M. Maiman‡‡
  1. *Radiation Oncology, St. Joseph's Hospital/Cancer Institute, Fred J. Woods Radiation Center, Tampa, Florida
  2. Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana
  3. Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York
  4. §Anatomic Pathology, University of Iowa, Iowa City, Iowa
  5. Department of OB/GYN, University of Oklahoma, Health Sciences Center, Oklahoma City, Oklahoma
  6. Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, Mississippi
  7. #Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon
  8. **Department of OB/GYN, University of Alabama at Birmingham, Birmingham, Alabama
  9. ††Department of Gynecologic Oncology, University of California Medical Center, Irvine, California
  10. ‡‡Department of Gynecologic Oncology, Staten Island University Hospital, Staten Island, New York
  1. Address correspondence and reprint requests to: Alison Calkins, MD, St. Joseph's Hospital/Cancer Institute, Fred J. Woods Radiation Center, 3001 W, Dr. M.L. King Jr. Blvd, Tampa, FL 33607, USA. Email: a_calkins{at}; and Denise Mackey, Gynecologic Oncology Group, Administrative Office, Four Penn Center, 1600 JFK Blvd, Suite 1020, Philadelphia, PA 19103, USA. Email: dmackey{at}


To determine the frequency of positive human immunodeficiency virus (HIV) serostatus among North American women 50 years of age or younger with invasive cervical cancer and to define their tolerance to treatment. Consenting patients with newly diagnosed invasive cervical cancer, age 50 or younger were tested by enzyme-linked immunosorbent assay. The study design anticipated that approximately 3% of patients would be HIV positive. After the accrual of 913 eligible and evaluable patients, interim analysis revealed that only 9/913 (∼1%) patients were HIV seropositive, indicating that it would not be feasible to achieve the study objective. The study was closed to further accrual. Between 1994 and 1997, the frequency of positive HIV serostatus among North American women with newly diagnosed cervical cancer was quite low. As a consequence, no evaluation of response to treatment or treatment tolerance can be made.

  • HIV testing
  • invasive cervical carcinoma

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.